Understanding the Unique Adverse Events Associated With Immunotherapy Agents
Benjamin P. Levy, MD, clinical director of Medical Oncology at John Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, discusses the unique adverse events with immunotherapy agents and how physicians can work together to overcome these challenges.
Benjamin P. Levy, MD, clinical director of Medical Oncology at John Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, discusses the unique adverse events (AEs) with immunotherapy agents and how physicians can work together to overcome these challenges.
The therapeutic algorithms have changed with the use of immunotherapy, especially in lung cancer, Levy says. The AEs found with immunotherapy agents can affect any organ and can be T cell-, antibody-, or cytokine-mediated.
While a lot of the pathophysiology has been ironed out, physicians should still be wary of the side effects that can arise in their patients. Levy encourages physicians to collaborate with a multidisciplinary team and take a proactive approach with these AEs.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
